What is the role of data in driving efficiency in cancer care? An All.Can policy paper

All.Can is developing a policy paper that takes a forward looking view on how we can evolve our health care systems and policy frameworks to enable data to drive greater efficiency in cancer care.

Why this paper?

Data are a key driver of efficiency: they underpin a learning healthcare system and can guide better use of resources to achieve better outcomes for patients.

The COVID-19 pandemic has magnified the value of data collection and sharing in oncology. But it has also exposed the fact that we are still far from the having an ideal, ready-to-use data system that can inform best practice.

Addressing existing gaps in our data ecosystem is a matter of urgency if we want to ensure the long-term sustainability of healthcare systems.

The paper will be launched in March 2021.

Our research question?

The key research question this policy paper is trying to address is: How can the collection and use of data improve or potentially improve the efficiency of cancer care?

But it will also look into:

  • How are data currently used along the patient care pathway?
  • How could data contribute to greater efficiency at each stage of the pathway?
  • What does the evidence tell us in terms of the role of data in driving efficiency in cancer care?
  • What are some of the key challenges with the current use of data and how can they be addressed?
  • What key recommendations can be made to guide policy change that will create an enabling environment for the optimisation of data in cancer care?

Aims and Objectives

We define data as:

… Any data describing a person’s health, their healthcare or anything affecting any health issues or diseases they may have. This includes information created by health and care professionals, as well as information generated by patients; from illnesses monitored through mobile applications and smart devices, to screening tests and nutritional data.

 Source: https://datasaveslives.eu/health-data-overview


Which data we are focused on?

For purposes of feasibility, we are focused on types of data deemed of most relevance in cancer, namely: patient-generated data, including PROMs and PREMs; registry data; electronic health records; genomics data; and digital biomarkers.


How are we defining efficiency?

We are using All.Can’s definition of efficiency: focusing resources on delivering the best outcomes for patients. We will analyse efficiency through the lens of the patient, looking at the use and potential of data to drive efficiency at each stage of the care pathway, from prevention to survivorship to end-of-life care.


Case studies

We will identify 15 case studies showing projects, programmes or initiatives where data have improved outcomes and efficiency for patients.


Geographic reach

The review will focus on Europe, with case studies drawn internationally.

The policy paper is based on a structured literature review, stakeholder interviews and case studies.

It is being developed with guidance from the All.Can Data Working Group
and an external advisory committee (please see Project governance).





The report has been developed by The Health Policy Partnership and Intacare International Ltd on behalf of All.Can International.
The day-to-day guidance of this report is led by the Data Working Group, with expert advice and input from the External Advisory Group.


All.Can International Data Working Group members

Sangeeta Agrawal, Helpsy
Antonella Cardone,
European Cancer Patient Coalition
Cattaneo, Novartis Dave Duplay, Medtera
Dave Duplay, Vital Options International
Caroline Falciola,
Alex Filicevas,
Miriam Gargesi,
Stefan Gijssels, Digestive Cancers Europe
Petra Hoogendoorn,
Agnieszka Krukowska,
Johnson & Johnson
Laura McDonald,
Bristol-Myers Squibb
Jan van Meerbeeck,
Antwerp University Hospital
Matthijs Van Meerveld,
Vivek Muthu,
Marivek Consulting
Kathy Oliver,
The International Brain Tumour Alliance
Titta Rosvall-Puplett,
Bristol-Myers Squibb
Christobel Saunders,
University of Western Australia
Julian Shepelev,
Puneet Singhal,
Henrietta Thole, Novartis
Veronica Zilli,
Johnson & Johnson

Matthew Hickey,
Intacare International Ltd (research lead)
Shannon Boldon, The Health Policy Partnership (research lead)
Suzanne Wait, The Health Policy Partnership (research lead)

External Advisory Committee

Suzanne Wait

Managing Director ,The Health Policy Partnership


Shannon Boldon

Consultant Researcher The Health Policy Partnership


Eduardo Pisani

CEO, All.Can International